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BACKGROUND: The purpose of this study was to detect postoperative persistent circulating tumour cells (CTCs) in stages II and III
colon cancer patients undergoing curative resection and so identify a subgroup of patients who are at high risk for early relapse.
METHODS: Four mRNA molecular markers including human telomerase reverse transcriptase, cytokeratin-19, cytokeratin-20, and
carcinoembryonic antigen (CEA) mRNA were used to detect CTCs in 141 stages II and III colon cancer patients undergoing curative
resection to determine the significance of CTCs in postoperative early relapse.
RESULTS: Out of 141 patients, postoperative early relapse and non-early relapse/no relapse was found in 48 (34.0%) patients and
93 (66.0%) patients, respectively. Univariately, postoperative early relapse was significantly correlated with lymph node metastasis
(P¼0.025), vascular invasion (P¼0.002), perineural invasion (P¼0.001), laparoscopic surgery (P¼0.019), high postoperative serum
CEA levels (P¼0.001), and presence of persistent postoperative CTCs (Po0.001). Using a multivariate proportional hazards
regression analysis, the presence of perineural invasion (P¼0.034; HR, 1.974; 95% CI: 1.290–3.861), high postoperative serum CEA
levels (P¼0.020; HR, 2.377; 95% CI: 1.273–4.255), and the presence of persistent postoperative CTCs (Po0.001; HR, 11.035; 95%
CI: 4.396–32.190), were demonstrated to be independent predictors for postoperative early relapse. Furthermore, the presence of
persistent postoperative CTCs was strongly correlated with a poorer disease-free and overall survival (both Po0.001).
CONCLUSIONS: This study suggests that molecular detection of persistent postoperative CTCs is a prognostic predictor of early relapse
in UICC stage II/III colon cancer patients, and thus could help to define patients with this tumour entity for an enhanced follow-up and
therapeutic program.
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Colorectal cancer (CRC) is a common neoplasia in the world
and also a major cause of cancer-related death (Frederiksen et al,
2010; Jemal et al, 2010). Although there have been significant
improvements in the treatment of advanced CRC patients, such as
the use of adjuvant chemotherapy, individuals with advanced
disease still have poor prognosis (Gallagher and Kemeny, 2010).
The use of adjuvant chemotherapy after curative surgery has been
demonstrated to improve outcome among patients with high-risk
stage II and stage III CRC (Andre et al, 2004; Wilkinson et al,
2010). Surgery remains the mainstay of therapy, but recurrence
after curative surgery of CRC occurs at a constant rate according to
the stage of the disease, and the more advanced the stage, the
greater the recurrent rate (Korner et al, 2005). The recurrence rates
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sin patients with stages I, II, and III CRC are 3.7, 13.3, and 30.8%,
respectively (Kobayashi et al, 2007). The recurrence of CRC is
also for the most part a time-related phenomenon, as 40–50% of
recurrences become apparent within the first year after initial
resection, and 90% within the first 4 years (Longo and Johnson,
2002). Recurrences in stages II and III patients showed a rapid
increase for the first 3 years, whereas the rate of those with stage I
cancer increased gradually and constantly for 5 years (Kobayashi
et al, 2007). Early relapse in CRC patients is attributed mainly to
the higher malignant entity (such as an unfavourable genotype,
deeper tumour invasion, lymph node metastasis, and advanced
cancer stage) and poor response to chemotherapy. There was a
consistent trend of poorer survival rates in cases of earlier relapse.
Therefore, it is valuable that we could detect the significant
predictive factors of postoperative early relapse.
For many decades, the depth of tumour invasion, local lymph
node involvement, and the presence or absence of distant meta-
stasis have been used as major prognostic factors to predict the
postoperative relapse in American Joint Commission on Cancer/
International Union Against Cancer (AJCC/UICC) colon cancer
patients (Edge et al, 2010). Efforts have concentrated on the early
detection of recurrent tumours to ensure adequate and effective
treatment to improve patient’s prognosis (Rodriguez-Moranta
et al, 2006). The identification of specific colon tumour-associated
molecular markers and the development of robustly accurate
assay method for effective disease monitoring would significantly
advance the early diagnosis of recurrence and subsequently
the effective treatment (Nannini et al, 2009). Undetected micro-
metastases contribute to the failure of primary curative surgery of
CRC (Zhang et al, 2005; Steinert et al, 2008). Therefore, the
detection of tumour shed cells in bloodstream is very important in
early recognition of postoperative CRC patients necessitating
further optimal therapy (Rahbari et al, 2010).
The concept of circulating tumour cells (CTCs) in the peripheral
blood of cancer patients was documented by Ashworth in 1869.
With the advance of molecular biology and refined techniques, the
identification of CTCs via nucleic acid-based methodology and
polymerase chain reaction (PCR) has been proven to be a useful tool
in the detection of occult metastases (Allan and Keeney, 2010). The
conventional PCR, reverse-transcriptase PCR, or real-time quanti-
tative PCR (Q-PCR) assays permit sensitive detection of CTCs, but
only one molecular marker can be checked at a time. As a result of
the heterogeneity of genetic biomarker expression in blood, a multi-
marker assay is regarded as more sensitive, time-saving, and cost-
effective than a single-marker assay (Yeh et al, 2006; Allan and
Keeney, 2010). Our previously developed membrane-array method
using multi-marker assay can detect CTCs as few as five cancer cells
in 1ml of peripheral blood (approximately one tumour cell per 10
6
white blood cells) in CRC patients (Wang et al, 2006; Yeh et al,
2006), and it is applied to the current investigation for the
postoperative surveillance of colon cancer patients.
So far, it remains a challenge to use proper molecular markers
for the detection, and then give optimal treatment of postoperative
early relapse in UICC stages II and III CRC patients (Allan and
Keeney, 2010; Rahbari et al, 2010). The aim of this study was to
determine the prognostic significance of persistent CTCs via
multiple blood sampling in the detection of postoperative early
relapse in stages II and III colon cancer patients, and thus help to
define patients with this tumour entity for an enhanced follow-up
and therapeutic program.
PATIENTS AND METHODS
Patients and samples collection
Between January 2004 and August 2008, a total of 381 AJCC/UICC
stages II and III colon cancer patients who underwent curative
resection from the Kaohsiung Medical University Hospital
were reviewed under the retrospective observational study.
Of 381 patients, 50 patients with other malignancies, those lost
to follow-up or followed up for o1 year, and those having had
surgical mortality or positive surgical resection margin for tumour
invasion were excluded. Curative surgery was defined as any gross
residual tumour that did not remain in the surgical bed and in
which the surgical resection margin was pathologically negative for
tumour invasion. To decrease the false-negative rate of CTCs in
predicting postoperative relapse, only cDNA from multiple
peripheral blood samples that could be obtained was enrolled,
therefore, 190 patients were excluded because of incomplete
multiple blood sampling postoperatively. Finally, 141 sets of cDNA
in 1 and 4 weeks after radical resection were entered into this
study. There was no statistical difference in the overall survival
between the 141 studied subjects and the 190 discarded ones
(P¼0.245). The development of new postoperative recurrent or
metastatic lesions was defined as postoperative relapse. Early
relapse was defined as local recurrence (tumour growth restricted
to the anastomosis or the region of the primary operation) or
distant metastasis (distant metastasis or diffuse peritoneal seeding)
within 1 year after radical resection. Postoperative surveillance
consisted of medical history, physical examination, and laboratory
studies including serum carcinoembryonic antigen (CEA) levels
every 3 months. Abdominal ultrasonography or computed tomo-
graphy was performed every 6 months, and chest radiography and
total colonoscopy were performed once a year. However, patients
with significantly elevated serum CEA level lasting 44–6 months,
abdominal or chest-computed tomography would be done before
the annual check-up. Patients were followed up at 3-monthly
intervals for 2 years and 6-monthly intervals thereafter. We
intensively followed up these enrolled patients until December
2009, and the median follow-up time was 40 months (range 16–72
months). Of these patients, 72 cases developed postoperative
relapse during the follow-up period, and 48 cases were classified
into early relapse. Patients diagnosed as either high-risk stage II or
III would receive adjuvant chemotherapy. Patients with risk factors
including tumour poorly differentiated, T4 stage, tumour perfora-
tion/obstruction, number of lymph nodes examined o12, or
lymphatic/vascular invasion were considered as high-risk stage II
cases. Intravenous 5-fluorouracil (5-FU)/leucovorin (LV) or oral
tegafur-uracil (UFUR)/LV was administrated to high-risk stage II
colon cancer patients, while 5-FU/LV/oxaliplatin or oral capecita-
bine was administrated to stage III colon cancer patients. The
duration of adjuvant chemotherapy was given for half a year.
Circulating tumour cells in peripheral blood of these 141 patients
were detected using our previously constructed membrane-array
method (Wang et al, 2006; Yeh et al, 2006). Briefly, a 4-ml sample of
peripheral blood was obtained from each CRC patient postoperatively
(1 and 4 weeks after operation) for total RNA isolation. To prevent
contamination of epithelial cells, peripheral blood samples were
obtained through a catheter inserted into a peripheral vessel, and the
first 5ml of blood were discarded. The definition of persistent CTCs in
studied subjects was defined as detectable CTCs by membrane-array
method postoperatively (both 1 and 4 weeks after operation). Written
informed consent was obtained from each subject and/or guardian.
Sample acquisition and subsequent use were also approved by the
hospital’s institutional review board. Preoperative staging methods
included chest X-ray, abdominal ultrasound, bone scan, and
abdominal-computed tomography. Clinical stage and pathological
features of primary tumours were defined according to the criteria of
the AJCC/UICC (Edge et al, 2010).
Detection of serum CEA
An additional 3-ml peripheral blood samples from 141 colon
cancer patients were obtained o1 week before operation
(preoperative) and 4 weeks after operation (postoperative). Serum
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sCEA levels were determined by means of an enzyme immunoassay
test kit (DPC Diagnostic Product Co., Los Angeles, CA, USA) with
the upper limit of 5ngml
–1 defined as normal according to the
manufacturers of the kits used.
mRNA isolation and first strand cDNA synthesis
Total RNA was extracted from the fresh whole blood of
preoperative/postoperative CRC patients using a QIAmp RNA
Blood Mini Kit (QIAGEN Inc., Valencia, CA, USA) according to
the manufacturer’s instructions. The RNA concentration was
determined spectrophotometrically on the basis of absorbance at
260nm. First strand cDNA was synthesised from total RNA by
using a RT–PCR kit (Promega Corp., Madison, WI, USA).
Membrane arrays
The procedure of the membrane-array method for the detection of
CTC-related mRNA molecular markers was performed according
to our previous study (Wang et al, 2006; Yeh et al, 2006). Patients
overexpressing all four molecular markers by membrane-array
methods in peripheral blood samples obtained postoperatively
(both 1 and 4 weeks after operation) were considered as positive
results of CTCs. In our previous investigation, the sensitivity limit
of this technique was established at approximately one tumour cell
per 10
6 white blood cells (five cells per 1ml blood) (Wang et al,
2006; Yeh et al, 2006).
Statistical analysis
All data were statistically analysed using the Statistical Package for
the Social Sciences, version 12.0 (SPSS Inc., Chicago, IL, USA).
A P-value o0.05 was considered statistically significant. Receiver
operating characteristics curve analyses were carried out to
determine the sensitivity and specificity for each mRNA marker of
membrane arrays (Wang et al, 2006; Yeh et al, 2006). The cut-off
values for each mRNA marker were set at points representing
the highest accuracy of analysis (minimal false-negative and
false-positive results). The difference between data obtained by
membrane array and real-time Q-PCR was calculated by using linear
regression and Pearson’s correlation. The univariate analysis of
clinicopathologic features and presence of CTCs between the two
groups (relapse group vs non-relapse group) was compared using
the w
2 test. Independent prognostic factors for postoperative relapse
were determined using a multivariate Cox proportional hazards
regression analysis. The disease-free survival rates and overall
survival rates were calculated by the Kaplan–Meier method, and the
differences in survival rates were analysed by the log-rank test.
RESULTS
The average age of 141 patients was 64.1 years (range 30–88 years,
Table 1). A total of 58 tumours (41.1%) were at the right-sided
colon and 83 (58.9%) at the left-sided colon. With regard to
the histological type of these tumours, 10 (7.1%) were well
differentiated, 103 (73.0%) were moderately differentiated, and
28 (19.9%) were poorly differentiated carcinoma. In view of
clinicopathologic characteristics of these 50 (35.5%) UICC stage II
and 91 (64.5%) UICC stage III colon cancer patients, 74 of 141
patients (52.5%) were identified to have vascular invasion, and 78
of 141 patients (55.3%) were found to have perineural invasion.
High serum CEA level (X5ngml
–1) was observed in 85 (60.3%)
of preoperative and 47 (33.3%) of postoperative colon cancer
patients, and persistent postoperative CTCs were detected in
51 (36.2%) of 141 colon cancer patients.
Table 2 discloses the correlation between persistent post-
operative CTCs and clinicopathologic features of 141 stages II
and III colon cancer patients. Under univariate analysis, depth
of invasion (P¼0.029), vascular invasion (Po0.001), perineural
invasion (P¼0.002), high preoperative serum CEA level
(P¼0.025), and high postoperative serum CEA level (Po0.001)
were significant in the presence of persistent postoperative CTCs.
If multivariate logistic regression analysis was used, the presence
of vascular invasion (P¼0.019; HR: 2.732, 95% CI: 1.176–6.394)
and high postoperative serum CEA level (P¼0.013; HR: 2.712, 95%
CI: 1.230–5.988) independently predicted the presence of
persistent postoperative CTCs (Table 3).
Table 4 shows the correlation between clinicopathologic features
and postoperative relapse of 141 stages II and III colon cancer
patients. Using univariate analysis, we found that lymph node
metastasis (P¼0.025), vascular invasion (P¼0.002), perineural
invasion (P¼0.001), type of surgery (P¼0.019), high post-
operative serum CEA level (P¼0.001), and presence of persistent
Table 1 Clinicopathologic features of 141 stages II and III colon cancer
patients undergoing curative resection
Variables Number (%)
Gender
Male/female 75(53.2)/66(46.8)
Age (y/o) 64.1±12.1
Maximum size (cm)
o5/X5 68(48.2)/73(51.8)
Location
Right-sided/left-sided
a 58(41.1)/83(58.9)
Depth of invasion
T1+T2/T3+T4 22(15.6)/119(84.4)
Lymph node metastasis
Yes/no 91(64.5)/50(35.5)
Vascular invasion
Yes/no 74(52.5)/67(47.5)
Perineural invasion
Yes/no 78(55.3)/63(44.7)
Histology
WD/MD/PD 10(7.1)/103(73.0)/28(19.9)
Preoperative CEA (ngml
 1)
o5/X5 56(39.7)/85(60.3)
Postoperative CEA (ngml
 1)
o5/X5 94(66.7)/47(33.3)
Type of surgery
Laparotomy/laparoscopy-assisted 110(78.0)/31(22.0)
Early postoperative relapse
Yes/no 48(34.0)/93(66.0)
Type of tumor
Adenocarcinoma/mucinous 119(84.4)/22(15.6)
Persistent postoperative CTCs
Yes/no 51(36.2)/90(63.8)
Adjuvant therapy
Yes/no 110(78.0)/31(22.0)
Abbreviations: CEA¼carcinoembryonic antigen; CTC¼circulating tumor cell;
MD¼moderately differentiated; PD¼poorly differentiated; WD¼well differen-
tiated.
aRight-sided, cecum+ascending colon+transverse colon; left-sided, descending
colon+sigmoid colon.
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postoperative early relapse. Using a multivariate Cox proportional
hazards regression analysis, the presence of perineural invasion
(P¼0.034; HR: 1.974, 95% CI: 1.290–3.861), high postoperative
serum CEA level (P¼0.020; HR: 2.377, 95% CI: 1.273–4.255), and
the presence of persistent CTCs (Po0.001; HR: 11.035, 95% CI:
4.396–32.190) were demonstrated to be independent predictors for
postoperative early relapse (Table 5). The median disease-free time
and overall survival time of the 141 studied patients were 45 and 62
months, respectively. Furthermore, both disease-free and overall
survival rate in patients with persistent CTCs (Figure 1) were
significantly lower than in those without persistent CTCs using
a log-rank test (both Po0.001).
DISCUSSION
It is notable to find that as many as 40–50% of recurrent CRC
develop within the first 1 year after ‘so-called’ curative surgery
Table 2 Correlation between persistent postoperative CTCs and
clinicopathologic features of 141 stages II and III colon cancer patients
using univariate analysis
a
Persistent postoperative CTCs
Yes (n¼51) No (n¼90)
No. (%) No. (%) P-value
a
Gender
Male/female 25(49.0)/26(51.0) 50(55.6)/40(44.4) 0.455
Age (y/o)
o65/X65 31(60.8)/20(39.2) 56(62.2)/34(37.8) 0.866
Maximum size (cm)
o5/X5 30(58.8)/21(41.2) 38(42.2)/52(57.8) 0.058
Location
Right-sided/left-sided
b 26(51.0)/25(49.0) 32(35.6)/58(64.4) 0.074
Depth of invasion
T1+T2/T3+T4 4(7.8)/47(92.2) 20(22.2)/70(77.8) 0.029
Lymph node metastasis
Yes/no 35(68.6)/16(31.4) 56(62.2)/34(37.8) 0.445
Vascular invasion
Yes/no 38(74.5)/13(25.5) 36(40.0)/54(60.0) o0.001
Perineural invasion
Yes/no 37(72.5)/14(27.5) 41(45.6)/49(54.4) 0.002
Histology
WD+MD/PD 44(86.3)/7(13.7) 68(75.6)/22(24.4) 0.130
Preoperative CEA (ngml
–1)
o5/X5 14(27.5)/37(72.5) 39(46.7)/54(53.3) 0.025
Postoperative CEA (ngml
–1)
o5/X5 24(47.1)/27(52.9) 70(77.8)/20(22.2) o0.001
Adjuvant therapy
Yes/no 43(84.3)/8(15.7) 67(74.4)/23(25.6) 0.174
Abbreviations: CEA¼carcinoembryonic antigen; CTC¼circulating tumor cell;
MD¼moderately differentiated; PD¼poorly differentiated; WD¼well differen-
tiated;
aw
2 test.
bRight-sided, cecum+ascending colon+transverse colon; left-sided,
descending colon+sigmoid colon.
Table 3 Correlation between persistent postoperative CTCs and
clinicopathologic features of 141 stages II and III colon cancer patients
using multivariate logistic regression analysis
Variables Coefficient s.e. P-value Hazard ratio
a
Depth (T3+T4/T1+T2) 0.699 0.627 0.264 3.012 (0.589–9.849)
Vascular invasion (yes/no) 1.006 0.430 0.019 2.732 (1.176–6.394)
Perineural invasion (yes/no) 0.496 0.433 0.252 1.642 (0.703–3.831)
Postoperative CEA (X5/o5) 0.999 0.404 0.013 2.717 (1.230–5.988)
Abbreviations:CTC¼circulating tumor cells; CEA¼carcinoembryonic antigen
(ngml
–1); s.e.¼standard error.
aValues in parentheses are 95% confidence intervals.
Table 4 Correlation between postoperative relapse pattern and
clinicopathologic features of 141 stages II and III colon cancer patients
using univariate analysis
Early relapse
(n¼48)
Non-early relapse/
No relapse (n¼93)
No. (%) No. (%) P-value
a
Gender
Male/female 23(47.9)/25(52.1) 52(55.9)/41(44.1) 0.367
Age (y/o)
o65/X65 28(58.3)/20(41.7) 59(63.4)/34(36.6) 0.554
Maximum size (cm)
o5/X5 26(54.2)/22(45.8) 42(45.2)/51(54.8) 0.311
Location
Right-sided/left-sided
b 24(50.0)/24(50.0) 59(43.4)/34(36.6) 0.124
Depth of invasion
T1+T2/T3+T4 5(10.4)/43(89.6) 19(20.4)/74(79.6) 0.134
Lymph node metastasis
Yes/no 37(77.1)/11(22.9) 54(58.1)/39(41.9) 0.025
Vascular invasion
Yes/no 34(70.8)/14(29.2) 40(43.0)/53(57.0) 0.002
Perineural invasion
Yes/no 36(75.0)/12(25.0) 42(45.2)/51(54.8) 0.001
Histology
WD+MD/PD 40(83.3)/8(16.7) 72(77.4)/21(22.6) 0.410
Preoperative CEA (ngml
 1)
o5/X5 17(35.4)/31(45.6) 39(41.9)/54(58.1) 0.453
Postoperative CEA (ngml
 1)
o5/X5 23(47.9)/25(52.1) 71(76.3)/22(23.7) 0.001
Type of surgery
Laparotomy/
laparoscopy-assisted
32(66.7)/16(33.3) 78(83.9)/15(16.1) 0.019
Type of tumor
Adenocarcinoma/
mucinous
43(89.6)/5(10.4) 76(81.7)/17(18.3) 0.223
Adjuvant therapy
Yes/no 37(77.1)/11(22.9) 73(78.5)/20(21.5) 0.848
Persistent postoperative CTCs
Yes/no 37(77.1)/11(22.9) 14(15.1)/79(84.9) o0.001
Abbreviations: CEA¼carcinoembryonic antigen; CTC¼circulating tumor cell;
MD¼moderately differentiated; PD¼poorly differentiated; WD¼well differen-
tiated.
aw
2 test.
bRight-sided, cecum+ascending colon+transverse colon; left-sided,
descending colon+sigmoid colon.
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gical factors or undetected micrometastases actually exist and may
have an important role in subsequent relapse (Zhang et al, 2005;
Steinert et al, 2008). Tumour relapse after curative resection of
CRC is attributed to tumour cell dissemination, currently under-
determined by standard TNM classification. There is often
significant heterogeneity of tumour behaviour and variable patient
outcome, which is unexplainable by pathologic factors alone. That
is to say, not all CRC patients with early UICC stage tumours are
cured and not all patients with advanced ones die from their
disease. This resulted in a number of efforts to develop more
accurate staging protocols to refine subsets appropriate for
targeted therapy (Greene, 2006; Roukos et al, 2007; Sun et al,
2009).
Disseminating tumour cells were suggested to shed from the
primary neoplasm into circulation before or during operation
(Yamaguchi et al, 2000). Accumulated reports have documented
the presence of CTCs in pre- or postoperative CRC patients, and
this would probably lead to postoperative relapse among these
patients (Yamaguchi et al, 2000; Molnar et al, 2001; Zhang et al,
2005; Wong et al, 2009; Peach et al, 2010). The fact that about half
of CRC patients relapse within 1 year after curative surgery
emphasises the urgent need for finding practical diagnostic tools to
detect CTCs to improve prediction of recurrence with conventional
UICC stage. This study has demonstrated that stages II–III colon
cancer patients identified with persistent postoperative CTCs using
multi-marker membrane-array method exhibit higher incidence of
postoperative early relapse and poorer disease-free and overall
survival rate. Consistent results are obtained from a recently
published meta-analytic report by (Rahbari et al, 2010), whose
analysis enrolled a total of 3094 CRC patients from 36 eligible
studies. Pooled analysis shows that detection of CTCs in the
peripheral blood indicates poorer recurrence-free survival
(HR¼3.24, 95% CI: 2.06–5.10) and overall survival (HR¼2.28,
95% CI: 1.55–3.38). Our previous report (Uen et al, 2008) studied
438 stages I–III CRC patients undergoing curative resection, and
137 of them had presence of both pre- and postoperative CTCs that
was strongly correlated with poorer relapse-free survival rates in
any of colorectal, colon or rectal cancer groups. Early relapse cases
had significantly lower overall survival rates than non-early relapse
cases either in colon cancer or in rectal cancer patients (Tsai et al,
2009). Consequently, through multiple blood sampling, this study
emphasised that persistent postoperative CTCs (lasting for 4 weeks
postoperatively) might have a role in the early identification of
postoperative early relapse in colon cancer patients, and more
intensive therapies may be considered among these patients.
On the contrary, some reports have conflicting results regarding
the prognostic role of CTCs in CRC patients (Bessa et al, 2001,
2003). The major cause of discrepancy between those reports and
ours may be that only a single molecular marker was used to check
CTCs in pre- or postoperative CRC patients in their studies, which
was thought to be more underestimated compared with a multi-
marker method (Yeh et al, 2006; Allan and Keeney, 2010). In addi-
tion, small and inhomogeneous patient groups were also attributed
to the aetiology of discrepancy between those reports and our
results. In fact, there are 22.9% (11 out of 48) false-negative and
Table 5 Correlation between postoperative early relapse and clinicopathologic features of 141 stages II and III colon cancer patients using multivariate cox
proportional hazards regression analysis
Variables Coefficient s.e. P-value
a Hazard ratio
b
Surgery (laparoscopy/laparotomy) 0.382 0.379 0.414 1.465 (0.697–3.077)
Lymph node metastasis (yes/no) 0.389 0.349 0.265 1.475 (0.745–2.923)
Vascular invasion (yes/no) 0.585 0.593 0.288 1.392 (0.402–3.786)
Perineural invasion (yes/no) 0.875 0.611 0.034 1.974 (1.290–3.861)
Postoperative CEA (X5/o5) 1.237 0.645 0.020 2.377 (1.273–4.255)
Persistent postoperative CTCs (yes/no) 1.832 0.613 o0.001 11.035 (4.396–32.190)
Abbreviations: CTC¼circulating tumor cells; CEA¼carcinoembryonic antigen (ngml
–1); s.e.¼standard error.
aCox proportional hazards regression analysis.
bValues in
parentheses are 95% confidence intervals.
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Figure 1 (A) Cumulative disease-free survival of 141 stages II and III
colon cancer patients according to the persistent postoperative presence of
CTCs. Colon cancer patients with persistent CTCs in peripheral blood
showed a significantly poorer disease-free survival than those without
CTCs in peripheral blood (Po0.001). (B) Cumulative overall survival of
141 stages II and III colon cancer patients according to the persistent
postoperative presence of CTCs. Colon cancer patients with persistent
postoperative CTCs in peripheral blood showed a significantly poorer
overall survival than those without CTCs in peripheral blood (Po0.001).
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relapses in postoperative stages II–III colon cancer patients using
our multi-marker membrane-array method, suggesting that there
is room for the refinement of this method. The false-negative
of our multi-marker array method in predicting postoperative
early relapse, at least in part, might result from CTCs inter-
mittently spreading into the bowel bloodstream, and the hetero-
geneous biologic nature of the tumour itself which cannot
overexpress all four molecular markers (Wang et al, 2006). In
our study, the definition of early relapse is clinically detectable
tumour within 1 year after operation. Fourteen patients (14 out
of 93, 15.1%) had false-positive results, which meant they had
positive postoperative CTCs but did not have early relapse during
follow-up. One of the explanations is inadequate follow-up time to
detect recurrent lesions. However, some of them (24 out of 93,
25.8%) did have tumour relapse 41 year after the operation.
Furthermore, few cancer cells shed into the bloodstream can
establish a successful metastasis, and that also can make a false-
positive result (Wang et al, 2006). Therefore, extending the follow-
up period and/or creating new probes to replace the present one
may improve the false-positive/negative rates of our membrane-
array method.
The positive rate of persistent CTCs (36.2%, 51 out of 141) is
parallel to the rate of abnormal elevated serum CEA (33.3%, 47 out
of 141) in our postoperative stages II–III colon cancer patients.
Both of these two variables have significant roles in predicting
early relapse of our studied patients either with univariate or
multivariate analysis. Besides, postoperative high CEA level is also
an independent predictor of the presence of persistent CTCs in our
studied patients (Table 3). Previously, pre- and postoperative
abnormal serum CEA levels in CRC patients have been documen-
ted as predictors of deeper local invasion of tumours, higher risk of
occult metastases or higher rates of postoperative relapse (McCall
et al, 1994; Wiratkapun et al, 2001). In fact, our recent work
further indicated that molecular detection of postoperative CTCs is
helpful in the early prediction of postoperative relapse in CRC
patients with normal perioperative serum CEA levels, with a
median leading time of 6 months before the measurement of
elevated CEA values (Wang et al, 2007). Consequently, post-
operative detection of CTCs would be a supplementary diagnostic
tool to conventional serial check of serum CEA in the ‘early’
recognition of early relapse in stages II–III colon cancer patients
receiving curative surgery.
Perineural invasion is a distinct pathologic entity, yet less
common than lymphovascular invasion observed in CRC patients
(Washington, 2008). As perineural invasion is often associated
with high tumour grade and stage, it is thought of as an ominous
prognostic sign in histological examination (Washington, 2008;
Liebig et al, 2009b). Liebig et al (2009a,b) reviewed and studied
perineural invasion in CRC patients, and found that it was a
strongly independent predictor of postoperative outcome in these
patients. They indicated that among node-negative CRC patients,
the 5-year disease-free survival rate for negative perineural
invasion patients was almost three-fold greater than for positive
perineural invasion cases (82 vs 29%, respectively) (Liebig et al,
2009a). Similar results were found for overall survival rate, where
the 5-year overall survival rate for node-negative patients with
positive perineural invasion was 43%, compared with 87% for
patients without perineural invasion (Liebig et al, 2009a).
Consistent with these investigations, this study also showed that
perineural invasion is a significant independent predictor in
detecting early relapse of stages II–III colon cancer patients.
According to the multivariate analysis, persistent postoperative
CTCs is a more powerful predictor, either compared with
conventional postoperative CEA level or with perineural invasion
(Table 5). Actually, 11 patients in our study with normal
postoperative CEA level and no histological perineural invasion
are correctly predicted to have an early relapse by persistent CTCs.
Therefore, detection of CTCs is superior to elevated CEA level or
positive perineural invasion in identifying early relapse of post-
operative stages II–III CRC patients. Although CTCs testing is
currently more expensive than traditional CEA measurement
or histological examination, it can be assumed that if multiple
times point testing becomes more routine, a reduction in cost
per test could be anticipated. Moreover, earlier detection of
recurrent malignancy can bring more therapeutic benefits by
detecting postoperative CTCs in patients and save more medical
expenditures.
In summary, our study demonstrates that in addition to the
check of perineural invasion and high postoperative CEA level, the
persistent presence of postoperative CTCs via multiple blood
sampling is a useful supplementary tool in detecting early relapse
and survival rate of stages II–III colon cancer patients undergoing
curative surgery. Certainly, there is a need for large, well-designed
prospective trials to verify the clinical significance of CTCs in
postoperative early relapse in CRC patients.
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